Totality Biosciences is half way through MassChallenge Switzerland in Lausanne.

Totality Biosciences is the exclusive developer of a groundbreaking synthetic biology platform that leverages genetically engineered plants to produce the full spectrum of human milk oligosaccharides (HMOs). We will be the first to unleash an unprecedented catalogue of unique bioprotective compounds to address gut inflammation and more from birth and beyond. Our approach has the potential to produce 5X more HMO structures for product development compared with current R&D libraries, and we have the only platform with the potential to produce all 200 HMOs from breast milk at scale. The technology supports the 1000X capacity increase that is required to address the demand for HMOs that is currently unsatisfied by incumbents, and our CSO’s peer-reviewed TEA published in Nature Foods supports a 10X reduction in minimum selling price compared with microbial production. The company aims to democratize access to full-spectrum HMOs and revolutionize human health, from life-saving applications for pre-term infants to health optimization across the lifespan.